Skip to main content

VIR

Stock
Health Care
Biotechnology

Performance overview

VIR Price
Price Chart

Forward-looking statistics

Beta
0.91
Risk
96.28%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.

Company info

SectorHealth Care
IndustryBiotechnology
Employees574
Market cap$1.5B

Fundamentals

Enterprise value-$8.8M
Revenue$20.9M
Revenue per employee
Profit margin98.67%
Debt to equity9.21

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$4.23
Dividend per share
Revenue per share$0.15
Avg trading volume (30 day)$6M
Avg trading volume (10 day)$4M
Put-call ratio

Macro factor sensitivity

Growth-2.4
Credit+4.0
Liquidity+0.6
Inflation-7.1
Commodities-1.5
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio-1.40
Price to sales34.66
P/E Ratio-1.40
Enterprise Value to Revenue-0.42
Price to book0.69

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Surging Earnings Estimates Signal Upside for Virtu Financial (VIRT) Stock

Virtu Financial (VIRT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Investment Research (July 18, 2025)
Will Virtu Financial (VIRT) Beat Estimates Again in Its Next Earnings Report?

Virtu Financial (VIRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research (July 11, 2025)
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?

Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research (July 10, 2025)
Should Value Investors Buy Virco Manufacturing (VIRC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research (July 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free